De novo donor‐specific HLA antibodies after combined intestinal and vascularized composite allotransplantation — a retrospective study
Combining vascularized composite allotransplantation (VCA) with intestinal transplantation to achieve primary abdominal closure has become a feasible procedure. Besides facilitating closure, the abdominal wall can be used to monitor intestinal rejection. As the inclusion of a VCA raises the possibil...
| Main Authors: | , , , , , , , , , |
|---|---|
| 格式: | Journal article |
| 語言: | English |
| 出版: |
Wiley
2017
|
| _version_ | 1826291931114635264 |
|---|---|
| author | Weissenbacher, A Vrakas, G Chen, M Reddy, S Allan, P Giele, H Barnardo, M Vaidya, A Friend, P Fuggle, S |
| author_facet | Weissenbacher, A Vrakas, G Chen, M Reddy, S Allan, P Giele, H Barnardo, M Vaidya, A Friend, P Fuggle, S |
| author_sort | Weissenbacher, A |
| collection | OXFORD |
| description | Combining vascularized composite allotransplantation (VCA) with intestinal transplantation to achieve primary abdominal closure has become a feasible procedure. Besides facilitating closure, the abdominal wall can be used to monitor intestinal rejection. As the inclusion of a VCA raises the possibility of an enhanced alloimmune response, we investigated the incidence and clinical effect of de novo donor‐specific HLA antibodies (dnDSA) in a cohort of patients receiving an intestinal transplant with or without a VCA. The sequential clinical study includes 32 recipients of deceased donor intestinal and VCA transplants performed between 2008 and 2015; eight (25%) modified multivisceral transplants and 24 (75%) isolated small bowel transplants. A VCA was used in 18 (56.3%) cases. There were no episodes of intestinal rejection without VCA rejection. Fourteen patients (14 of 29; 48.3%) developed dnDSA. In the VCA group, fewer patients developed dnDSA; six of 16 (37.5%) VCA vs. eight of 13 (61.5%) non‐VCA. There was no statistically significant difference in one‐ and 3‐year overall graft survival stratified for the presence of dnDSA; P = 0.286. In the study, there is no evidence that the addition of a VCA increases the incidence of dnDSA formation compared to transplantation of the intestine alone. |
| first_indexed | 2024-03-07T03:06:54Z |
| format | Journal article |
| id | oxford-uuid:b2dbfe23-3d7c-48d0-af0c-e2824ca959b8 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T03:06:54Z |
| publishDate | 2017 |
| publisher | Wiley |
| record_format | dspace |
| spelling | oxford-uuid:b2dbfe23-3d7c-48d0-af0c-e2824ca959b82022-03-27T04:14:46ZDe novo donor‐specific HLA antibodies after combined intestinal and vascularized composite allotransplantation — a retrospective studyJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:b2dbfe23-3d7c-48d0-af0c-e2824ca959b8EnglishSymplectic Elements at OxfordWiley2017Weissenbacher, AVrakas, GChen, MReddy, SAllan, PGiele, HBarnardo, MVaidya, AFriend, PFuggle, SCombining vascularized composite allotransplantation (VCA) with intestinal transplantation to achieve primary abdominal closure has become a feasible procedure. Besides facilitating closure, the abdominal wall can be used to monitor intestinal rejection. As the inclusion of a VCA raises the possibility of an enhanced alloimmune response, we investigated the incidence and clinical effect of de novo donor‐specific HLA antibodies (dnDSA) in a cohort of patients receiving an intestinal transplant with or without a VCA. The sequential clinical study includes 32 recipients of deceased donor intestinal and VCA transplants performed between 2008 and 2015; eight (25%) modified multivisceral transplants and 24 (75%) isolated small bowel transplants. A VCA was used in 18 (56.3%) cases. There were no episodes of intestinal rejection without VCA rejection. Fourteen patients (14 of 29; 48.3%) developed dnDSA. In the VCA group, fewer patients developed dnDSA; six of 16 (37.5%) VCA vs. eight of 13 (61.5%) non‐VCA. There was no statistically significant difference in one‐ and 3‐year overall graft survival stratified for the presence of dnDSA; P = 0.286. In the study, there is no evidence that the addition of a VCA increases the incidence of dnDSA formation compared to transplantation of the intestine alone. |
| spellingShingle | Weissenbacher, A Vrakas, G Chen, M Reddy, S Allan, P Giele, H Barnardo, M Vaidya, A Friend, P Fuggle, S De novo donor‐specific HLA antibodies after combined intestinal and vascularized composite allotransplantation — a retrospective study |
| title | De novo donor‐specific HLA antibodies after combined intestinal and vascularized composite allotransplantation — a retrospective study |
| title_full | De novo donor‐specific HLA antibodies after combined intestinal and vascularized composite allotransplantation — a retrospective study |
| title_fullStr | De novo donor‐specific HLA antibodies after combined intestinal and vascularized composite allotransplantation — a retrospective study |
| title_full_unstemmed | De novo donor‐specific HLA antibodies after combined intestinal and vascularized composite allotransplantation — a retrospective study |
| title_short | De novo donor‐specific HLA antibodies after combined intestinal and vascularized composite allotransplantation — a retrospective study |
| title_sort | de novo donor specific hla antibodies after combined intestinal and vascularized composite allotransplantation a retrospective study |
| work_keys_str_mv | AT weissenbachera denovodonorspecifichlaantibodiesaftercombinedintestinalandvascularizedcompositeallotransplantationaretrospectivestudy AT vrakasg denovodonorspecifichlaantibodiesaftercombinedintestinalandvascularizedcompositeallotransplantationaretrospectivestudy AT chenm denovodonorspecifichlaantibodiesaftercombinedintestinalandvascularizedcompositeallotransplantationaretrospectivestudy AT reddys denovodonorspecifichlaantibodiesaftercombinedintestinalandvascularizedcompositeallotransplantationaretrospectivestudy AT allanp denovodonorspecifichlaantibodiesaftercombinedintestinalandvascularizedcompositeallotransplantationaretrospectivestudy AT gieleh denovodonorspecifichlaantibodiesaftercombinedintestinalandvascularizedcompositeallotransplantationaretrospectivestudy AT barnardom denovodonorspecifichlaantibodiesaftercombinedintestinalandvascularizedcompositeallotransplantationaretrospectivestudy AT vaidyaa denovodonorspecifichlaantibodiesaftercombinedintestinalandvascularizedcompositeallotransplantationaretrospectivestudy AT friendp denovodonorspecifichlaantibodiesaftercombinedintestinalandvascularizedcompositeallotransplantationaretrospectivestudy AT fuggles denovodonorspecifichlaantibodiesaftercombinedintestinalandvascularizedcompositeallotransplantationaretrospectivestudy |